Regeneron Pharmaceuticals Inc. (REGN) Earns “Buy” Rating from Roth Capital
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by equities research analysts at Roth Capital in a research report issued on Wednesday. They currently have a $520.00 price objective on the biopharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 34.70% from the company’s current price.
A number of other equities analysts have also recently commented on the stock. RBC Capital Markets reaffirmed an “outperform” rating and set a $648.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 4th. Robert W. Baird reaffirmed a “neutral” rating and set a $448.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 4th. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Leerink Swann set a $530.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 3rd. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 30th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 3.20% during midday trading on Wednesday, reaching $373.71. 498,424 shares of the company’s stock traded hands. The stock has a 50-day moving average of $400.58 and a 200 day moving average of $392.25. The company has a market cap of $39.10 billion, a P/E ratio of 58.30 and a beta of 1.31. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/regeneron-pharmaceuticals-inc-regn-earns-buy-rating-from-roth-capital.html
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The firm earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the business posted $2.89 earnings per share. The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in REGN. Raymond James Trust N.A. bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $278,000. Jacobs & Co. CA bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $345,000. Fisher Asset Management LLC raised its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the last quarter. Harding Loevner LP raised its stake in Regeneron Pharmaceuticals by 91.7% in the third quarter. Harding Loevner LP now owns 318,565 shares of the biopharmaceutical company’s stock worth $128,070,000 after buying an additional 152,425 shares during the last quarter. Finally, Advisory Services Network LLC raised its stake in Regeneron Pharmaceuticals by 80.7% in the third quarter. Advisory Services Network LLC now owns 600 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 268 shares during the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.